SpringWorks Therapeutics, Inc.
SWTX evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Lead Asset:
- gomekli (Phase 2)
What it means
What to watch
Prepared research question
What matters most for SWTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates · 3 clinical trials for SpringWorks Therapeutics, Inc..
Run SpringWorks Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SpringWorks Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is SpringWorks Therapeutics, Inc.'s lead drug candidate?
SpringWorks Therapeutics, Inc.'s most advanced tracked candidate is gomekli (Phase 2) for Treatment of solid tumors harboring MAPK pathway aberrations, including pediatric low-grade glioma.
Who is the CEO of SpringWorks Therapeutics, Inc.?
Saqib Islam Saqib is the chief executive officer of SpringWorks Therapeutics, Inc. (SWTX).
What therapeutic areas does SpringWorks Therapeutics, Inc. focus on?
SpringWorks Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.